Breed · Horse
Pony: adverse event reports
FDA breed label "Pony (unspecified)" · single-breed animals only
FDA's database holds 144 reports where the animal's breed is given as "Pony (unspecified)", shown here as Pony: 0.8% of reports about horses. Reports on crossbred animals are left out of breed pages.
9 reports arrived in the 12 months to March 2026, down 31% from 13 in the 12 months before. A breed's count mostly mirrors how common the breed is; registration and ownership figures by breed are not public data, so no per-animal rate can be given.
By active ingredient, the drugs named most often are pergolide mesylate, omeprazole and ivermectin + praziquantel. Pergolide mesylate is named in 58.3% of this breed's reports, a larger share than in reports about all horses (6.5%).
The terms listed most often are lack of efficacy - NOS (15.3%), anorexia (11.1%) and colic (7.6%). Lack of efficacy - NOS appears in 15.3% of reports, a larger share than in all horse reports (7.6%). 42% of reports stating seriousness were classed as serious, against 44.1% for horses overall.
Drugs named most often, by active ingredient
| Active ingredients recorded for the drug | Reports | Share of Pony reports | Share of all horse reports |
|---|---|---|---|
| Pergolide mesylate | 84 | 58.3% | 6.5% |
| Omeprazole | 19 | 13.2% | 9.9% |
| Ivermectin + Praziquantel | 9 | 6.3% | 14.4% |
| Firocoxib | 6 | 4.2% | 2.6% |
| Sucralfate | 4 | 2.8% | 1.7% |
| Detomidine Hydrochloride | 3 | 2.1% | 5.6% |
| Butorphanol Tartrate | 2 | 1.4% | 1.6% |
| Ceftiofur Crystalline Free Acid | 2 | 1.4% | 4.8% |
| Ciclesonide | 2 | 1.4% | 0.5% |
| Clodronate | 2 | 1.4% | 1.7% |
| Flunixin Meglumine | 2 | 1.4% | 3.5% |
| Ivermectin | 2 | 1.4% | 4.6% |
| Monensin | 2 | 1.4% | 1.6% |
| Pentobarbital Sodium + Phenytoin Sodium | 2 | 1.4% | 0.3% |
| Pentosan polysulfate sodium | 2 | 1.4% | 1% |
| Hyaluronate Sodium | 1 | 0.7% | 2.9% |
| Imidocarb Dipropionate | 1 | 0.7% | 0% |
| Misoprostol | 1 | 0.7% | 0.5% |
| Moxidectin | 1 | 0.7% | 7.4% |
| Moxidectin + Praziquantel | 1 | 0.7% | 2% |
Ordered by report count. Differences from the species column often come from body size (which drugs a breed is prescribed) and from how common the breed was in the years a drug sold most. FDA states that these data cannot be used to estimate risk or to compare one product with another. Brand and manufacturer names are masked by FDA in these records.
Signs listed in reports
share of Pony reports listing the termall horse reports
- Lack of efficacy - NOS[the product did not have the expected effect]15.3%22
- Anorexia[not eating]11.1%16
- Colic7.6%11
- Lethargy[unusually tired or inactive]7.6%11
- Behavioural disorder NOS[behaviour change, type not specified]6.3%9
- Death by euthanasia[the animal was euthanized]6.3%9
- Ineffective, cushings[legacy FDA term: the product did not have the expected effect (cushings)]6.3%9
- Laminitis5.6%8
- Diarrhoea[diarrhea]4.9%7
- Inappetence[reduced appetite]4.9%7
- Seizure NOS[seizure, type not specified]4.9%7
- Ineffective, gastric ulcer(s)[legacy FDA term: the product did not have the expected effect (gastric ulcer(s))]4.2%6
- Application site swelling[swelling where the product was applied]3.5%5
- Death3.5%5
- Lameness3.5%5
- Other abnormal test result NOS[abnormal laboratory result, type not specified]3.5%5
- Swollen mouth3.5%5
- Decreased appetite2.8%4
- Elevated gamma-glutamyl transferase (GGT)[a liver enzyme above the normal range]2.8%4
- Partial lack of efficacy[the product worked less well than expected]2.8%4
- Weight loss2.8%4
- Abscess NOS[NOS: not otherwise specified]2.1%3
- Anaphylactoid reaction[sudden allergic-type reaction]2.1%3
- Depression[dull, quiet or withdrawn]2.1%3
- Elevated creatinine[a kidney value above the normal range]2.1%3
Age and weight
Age of the animal
Weight of the animal
Coloured bar: Pony reports. Grey bar: all horse reports.
Trend and outcomes
Reports by month FDA received them. The newest months are incomplete because FDA posts reports with a delay of three to six months.
Outcome recorded in the report
Beside all horses
| Measure | Pony | All horses |
|---|---|---|
| Reports | 144 | 18,382 |
| Latest 12 months | 9 | 898 |
| Classed serious, of reports stating it | 42% | 44.1% |
| Death or euthanasia recorded, per 1,000 reports | 111.1 | 136 |
Questions about Pony reports
How many FDA adverse event reports involve Ponys?
144 reports through March 2026, 0.8% of reports about horses; 9 in the latest 12 months.
Which drugs are named most often in Pony reports?
By active ingredient: pergolide mesylate (84), omeprazole (19), ivermectin + praziquantel (9), firocoxib (6) and sucralfate (4). Brands are masked in the public data.
What signs are reported most for this breed?
lack of efficacy - NOS (15.3%), anorexia (11.1%), colic (7.6%), lethargy (7.6%) and behavioural disorder NOS (6.3%).
Is the Pony more sensitive to certain drugs?
Report counts cannot answer that. They show what was reported, not what a drug did, and they are not adjusted for how many Pony animals exist or were treated. Breed-related drug sensitivities that are established are described on FDA-approved labels; a veterinarian is the person to ask about an individual animal.
Why are crossbreds not included?
FDA records crossbred animals with one or more component breeds. Counting them under each component would double count, so breed pages use single-breed reports only. Crossbreds remain in the species totals.
How do I report a problem?
Call the drug company using the number on the label, or send Form FDA 1932a to FDA. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Animal & Veterinary adverse event bulk files released 28 Sep 2026, which hold reports FDA's Center for Veterinary Medicine received through 31 Mar 2026. openFDA masks brand and manufacturer names in these files, so drugs are counted by the active ingredients each record discloses and no figure is attributed to a brand, application or company. Ingredient names, and the separate reference lists of approved products, follow the FDA Green Book as of 1 Oct 2026. Breed names are FDA's labels rearranged into everyday order ("Pony (unspecified)" becomes "Pony"). No report text, lot numbers or reporter details are published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.